Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
The New Phytologist|December 17, 2013
A global analysis of bidirectional interactions in alpine plant communities shows facilitators experiencing strong reciprocal fitness costsChristian Schöb, Richard Michalet, Lohengrin A Cavieres, et al.
Ecology|September 26, 2015
The effects of foundation species on community assembly: a global study on alpine cushion plant communitiesZaal Kikvidze, Robin W Brooker, Bradley J Butterfield, et al.
Ecology Letters|January 26, 2013
Alpine cushion plants inhibit the loss of phylogenetic diversity in severe environmentsB J Butterfield, L A Cavieres, R M Callaway, et al.
Muscle & Nerve|July 6, 2023
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE studyThomas O Crawford, Kathryn J Swoboda, Darryl C De Vivo, et al.
The Lancet. Neurology|August 16, 2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
Neuromuscular Disorders : NMD|November 10, 2019
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studyDarryl C De Vivo, Enrico Bertini, Kathryn J Swoboda, et al.
Muscle & Nerve|April 16, 2022
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophyJeffrey M Statland, Craig Campbell, Urvi Desai, et al.
Ecology Letters|November 19, 2013
Facilitative plant interactions and climate simultaneously drive alpine plant diversityLohengrin A Cavieres, Rob W Brooker, Bradley J Butterfield, et al.
JCI Insight|March 22, 2019
A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapiesVéronique Bolduc, A Reghan Foley, Herimela Solomon-Degefa, et al.
Lancet (London, England)|July 29, 2026
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trialCraig M McDonald, Chet Villa, Jonathan H Soslow, et al.
Pageof 21